Inhibitor development in correlation to factor VIII genotypes.

Abstract excerpt

Alloantibodies (inhibitors) against factor VIII (FVIII) develop in 20-30% of patients with severe haemophilia A and render classical FVIII substitution therapy ineffective. Several studies have shown that genetic factors, the type of FVIII gene mutation and immune response genes (e.g. the Major Histocompatibility Complexes), influence the risk of inhibitor formation. In particular, the type of FVIII gene mutation...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antibodies
• Share to Antibody Formation
• Share to Epitopes